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literature the differentiation between salivary gland dysfunc-
tion due to cGVHD and long-term related high dose chemo-
therapy.
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL
TRANSPLANTATION (AUTOSCT) FOLLOWED BY REDUCED INTENSITY
(RI) ALLOGENEIC TRANSPLANTATION (ALLOSCT) IN CHILDREN AND
YOUNG ADULTS WITH RELAPSED/REFRACTORY LYMPHOMA
Bradley, M.B., Cooney, E., Harrison, L., George, D., Garvin, J., Del
Toro, G., Bessmertny, O., Cheung, Y.-K., Weiner, M., Kelly, K.,
Gewanter, R., Skerrett, D., Cairo, M.S. Children’s Hospital of New
York-Presbyterian, Columbia University, New York, NY
AlloSCT may be beneﬁcial to patients with relapsed Hodgkin’s
disease (HD) and non-Hodgkin’s lymphoma (NHL) by providing
a graft vs HD effect. MA AlloSCT is however associated with a
high incidence of regimen-related mortality (RRM) (Jones et al,
Blood 77:649, 1991). Carella et al (JCO 18:3918, 2000) demon-
strated the feasibility of MA AutoSCT followed by RI AlloSCT in
adults with refractory HD. We investigated MA AutoSCT fol-
lowed by RI AlloSCT in relapsed pediatric HD/NHL. Patients
were entered post reinduction therapy (2 CR  2 PR after Ifos/
Carbo/Etop, 1 CR after Ifos/Vinorelbine and 1 PR after Topo/
Ifos/Carbo). MA: Cyclo 1500 mg/m2  4d, BCNU 100 mg/m2 
3d, VP-16 800 mg/m2  3d, and AutoSCT. Patients with CD20
lymphoma (5/6) received Rituximab (375 mg/m2/wk/4) and 6
patients received IFRT (2-3 Gy). RI: Flu 30 mg/m2  5d, Bu 3.2
mg/kg  2d, and Thymoglobulin® 2.0 mg/kg  4d (UCB recip-
ients only) and AlloSCT (1 related 6/6 PBSC, 5 4/6 UCB). GVHD
prophylaxis: FK506 (0.03 mg/kg CIVI) on day-1-60 and MMF
(15 mg/kg) day 1-28. Five HD age 13-21 yrs, 2 stage IIA, 1
stage IIIB, 1 stage IVA, 1 stage IVB and 1 stage III ALCL, age 11,
have been treated. MA AutoSCT  RI AlloSCT were well toler-
ated in all patients. Median time to RI AlloSCT after MA Auto-
SCT was 121 d. Median F/U is 577 d. Toxicity: grade 3 hematuria
(n  1), grade 3/4 infection without neutropenia (n  3), grade 4
infection with neutropenia (n  2), grade 4 pulmonary ﬁbrosis
(n 1), grade 4 hearing loss (n 1) and grade 4 thrombocytopenia
(n  1). Following RI AlloSCT, myeloid recovery occurred on day
15 (MRD), day 18, 23, 15, 30, 45 days (UCBT), plate-
let recovery on day 11 (MRD), day 31, 170, 25, 62, NE
(UCBT). All patients achieved 100% donor chimerism by d180.
HD patients: 4/5 are NED at d 837, 836, 632 (deceased) and
147, respectively, 1/5 PD d 175. NHL: NED at d 522. One
patient developed grade II AGVHD of the gut which resolved with
steroids. One patient developed limited CGVHDwhich responded
to alternating CSA  Pred. One pt developed extensive CGVHD.
There has been one death (NRM) from infection d 632. The
estimated OS at 1 year is 100%. In summary, MA  AutoSCT
followed by IFRT, targeted monoclonal antibody therapy, and RI
AlloSCT is feasible and well tolerated in pediatric patients with
relapsed HD/NHL. A larger controlled study with longer follow
up is required to determine if this approach will reduce relapse
and/or long-term toxicity and improve EFS.
187
PERSISTENTLY LOW SERUM OSTEOPROTEGRIN LEVELS DURING THE
TREATMENT OF MULTIPLE MYELOMA PATIENTS PREDICTS WORSE
EVENT-FREE SURVIVAL
Moreb, J.S., Zucali, J.R., Roberts, C. University of Florida, Gainesville,
FL
Osteoprotegrin (OPG) functions as a secreted inhibitor of bone
resorption and its serum levels have been reported to be reduced in
patients with multiple myeloma (MM). In this study, serum and
urine OPG levels were prospectively measured in patients with
MM (stage II III) and in patients with other hematologic malig-
nancies (control group) and correlated to response to therapy.
Newly diagnosed as well as patients on maintenance therapy were
included. The MM and control group were well matched in terms
of age and gender, as well as time from diagnosis to enrollment.
Seventeen MM patients underwent autologous stem cell transplant
while none in the control group were transplanted. Blood and
urine samples were collected monthly, cytocentrifuged and stored
in frozen aliquots at 20° C until analyzed. OPG was measured
using an ELISA. Thus far data on 28 MM patients and 9 patients
with other hematologic malignancies (2 AML, 2 CML, 1 CLL, 2
NHL, 2 monoclonal gammopathy of unknown signiﬁcance) have
been analyzed. All patients were treated with monthly intravenous
bisphosphonate. The results reveal that OPG is detectable in the
urine and its levels correlate signiﬁcantly (r  0.77 and two-tailed
P  0.0032) with the degree of renal failure as reﬂected by serum
creatinine. Our results also show that the overall median serum
OPG level was lower in MM patients (1181 pg/mL), but not
signiﬁcantly different than that of the control group (1437 pg/mL).
However, 4 of 20 (20%) evaluable MM patients with adequate
follow-up had OPG serum levels that remained  1000 pg/mL
throughout the treatment. Their median event-free survival (EFS)
was 8 months compared with 19 months for the rest of the group
(P  0.023), while no signiﬁcant difference was detected in the
median overall survival. There was no OPG serum levels  1000
pg/mL during the follow-up of the control group. Among the 10
newly diagnosed MM patients enrolled in the study, only 2 (20%)
had low serum OPG at presentation, with no detectable urine
OPG. Median OPG serum levels were lower for MM patients
during induction therapy (940 pg/mL, n  7) in comparison to
those undergoing maintenance therapy (1536 pg/mL, n  8; P 
0.16). In conclusion, OPG urine as well as serum levels should be
monitored simultaneously since low serum levels may reﬂect high
OPG urinary loss. In addition, persistently low OPG serum levels
throughout treatment of MM patients may be a prognostic factor
for worse EFS.
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ASCT IN A YOUNG PATIENT WITH FEATURES OF POEMS SYNDROME
EVOLVING TO MULTIPLE MYELOMA
Roesler, W., Guenther, A., Schub, N., Winkler, J., Rascu, A., Repp, R.,
Gramatzki, M. Div. of Hematology/Oncology, Department of Medicine
III, University of Erlangen-Nuremberg, Erlangen, Germany
POEMS syndrome is a rare plasma cell dyscrasia characterised by
polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy and skin changes. The pathogenesis of the disease is
unclear. However, certain features are similar to multicentric
Castleman’s disease and HHV-8 infection. We report the case of a
patient with POEMS syndrome progressing to multiple myeloma
that was unresponsive to treatment with rituximab and standard
chemotherapy but improved considerably after ASCT. The 28 year
old patient presented with severe polyneuropathy. A low level IgG
lamda monoclonal gradient and a slight plasma cell inﬁltration of
the marrow was found. Hepatosplenomegaly, thrombocytosis,
polycythemia, plethora and low TSH was consistent with POEMS
syndrome. The patient had anti-HHV-8 antibodies and HHV-8-
DNA was found in her initial marrow examination. While reported
to be effective in Castleman’s disease, the patient was treated with
4 doses of rituximab, but did not respond. During the following 3
months the patient progressed to multiple myeloma with a bone
marrow involvement of  20% plasma cells. Atypical plasma cells
and a hypercellular megakaryopoesis were found. However, no
Table. Preliminary Results of Gallium-67 Scintigraphic Study on
Major Salivary Glands (n  18 patients)
Submandible
(n patients)
Parotid
(n patients)
Positive Negative Positive Negative
Before BMT 1 17 0 18
Day 30 after 5 9 3 11
Day  60 after 7 6 3 10
Day  100 after 7 6 4 9
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osteolytic or osteosclerotic bone lesions were detectable. HHV-8
DNA was no longer detectable in marrow or blood. The patient
received 4 cycles of idarubicine/dexamethasone. The response to
this treatment was minimal and an ASCT was planned. After
mobilisation chemotherapy with iphosphamide, epirubicine and
etoposide, 29.65 x 106 CD34-positive progenitor cells/kg could be
harvested with one leukapheresis. ASCT was performed after high
dose therapy with melphalan 200 mg/m2. Reinfusion of 14.83 
106 CD34-positive progenitor cells/kg and medication with G-
CSF resulted in engraftment on day 9. Restaging 5 weeks later
showed an excellent response. Bone marrow plasma cell inﬁltration
was no longer detectable and hypercellularity of megakaryopoesis
was markedly reduced. The platelet counts had returned to normal
and the pleural effusions had vanished. IgG and serum electro-
phoresis were normal while the immunoﬁxation remained positive
for IgG lamda. The polyneuropathy of the patient is continuously
improving. In conclusion, this case may represent an evolution
from possibly HHV-8 related POEMS syndrome to multiple my-
eloma. Despite lack of response to standard chemo- and immuno-
therapy ASCT seems to be a useful therapeutic option in patients
with signs of POEMS syndrome.
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RNA-LOADING OF CMRF-56 POSITIVE BLOOD DENDRITIC CELLS IS A
PROMISING STRATEGY FOR MULTIPLE MYELOMA IMMUNOTHERAPY
Turtle, C.J.1, Radford, K.J.1, Allan, C.P.1, Kassianos, A.1, Kato, M.1,
Vuckovic, S.1, MacDonald, K.J.1, Lopez, J.A.2, Jackson, D.C.3, Wright,
S.4, Taylor, K.4, Marlton, P.5, Gill, D.5, Hart, D.N.J.1 1. Mater
Medical Research Institute, Brisbane, QLD, Australia; 2. Queensland
Institute of Medical Research, Brisbane, QLD, Australia; 3. University
of Melbourne, Melbourne, VIC, Australia; 4. Mater Adult Hospital,
Brisbane, QLD, Australia; 5. Princess Alexandra Hospital, Brisbane,
QLD, Australia
Immunologic responses to the malignant plasma cells of multiple
myeloma (MM) patients are beinginvestigated for their ability to
prevent disease relapse after autologous and allogeneic haemato-
poietic stem cell transplantation. Dendritic cells (DC) are special-
ized leukocytes that have the capacity to prime and direct an
immune response against tumour-associated antigens (TAA). We
have used new Trucount® technology to evaluate the whole blood
DC subset composition of healthy donors and MM patients. MM
donors have similar numbers of CD11c CD16 and
CD11cCD16-blood DC subsets but about half the number of
CD11c-CD123 blood DC compared to normal donors. A
CMRF-56 monoclonal antibody-based immunomagnetic selection
procedure was used to enrich blood DC for functional studies from
the peripheral blood mononuclear cells of healthy donors and MM
patients. CMRF-56 blood DC from MM patients are efﬁciently
activated ex vivo and induce autologous and allogeneic mixed lym-
phocyte responses. The CMRF-56 blood DC preparation is able
to present MHC class I -restricted peptide antigens and has been
used to generate cytotoxic T lymphocytes (CTL) against MM
-related TAA, hTERT and MUC1. We have optimised the load-
ing of CMRF -56 blood DC preparations with antigen-encoding
mRNA and have shown that enhanced green ﬂuorescent protein
mRNA is rapidly transl ated after electroporation into blood DC.
In addition, inﬂuenza matrix protein (FMP) mRNA -loaded blood
DC can process and present antigen to FMP-speciﬁc CTL clones
and prime FMP-speciﬁc CTL responses in whole PBMC popula-
tions. We are currently in the process of generating responses
against total RNA extracted from MM cell lines prior to initiating
a clinical trial of RNA-loaded CMRF-56 blood DC in patients.
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FREELITE; A NEW LABORATORY TOOL TO AIDE IN MONITORING
MULTIPLE MYELOMA AFTER TREATMENT
Staggs, B., Fender, B., Joseph, L. University of Arkansas for Medical
Sciences, Little Rock, AR
Background: Multiple Myeloma (MM) is a diagnosis based on
multiple parameters. Immunoglobulin levels, radiography, and
bone marrow morphology are all evaluated for diagnosis and dis-
ease monitoring. Each test examines a different aspect of the
disease. Conﬂicting values between these can obscure the disease
picture. In addition, there are several subsets of MM depending on
the immunoglobulin secreted. However, one thing is common to
all but 5% of MM patients; an excess of free light chains is
produced. A new laboratory test, Freelite™, easily and accurately
measures free light chains in the serum. Methods: One hundred
ﬁfty patients with MM who had undergone treatment, some in-
cluding bone marrow transplant, were prospectively examined.
Fifty were patients treated for free light chain MM. Seventy-two
were patients treated for IgG MM and 28 were patients treated for
IgA secreting MM. The current serum free light chains were
examined using Freelite™ and then correlated to the disease state
as identiﬁed by consensus of bone marrow biopsy, ﬂow cytometry
and electrophoresis. Results: Thirty-seven of the 50 patients
treated for free light chain MM currently had disease. All 37 had
markedly elevated serum free light chain levels. The 13 remaining
patients were diagnosed “negative” or “atypical” and 8 of these had
elevated serum free light chain levels. Forty-six of 100 patients
treated for IgG or IgA MM currently had disease. All 46 of these
had elevated serum free light chain levels. Fifty-four were diag-
nosed “negative” or “atypical” and 30 had elevated serum free light
chain levels. Discussion: In this broad analysis of the most com-
mon subtypes of MM, Freelite™ is 100% sensitive when correlated
to MM diagnosed by our standard methods. The issue then be-
comes the decreased speciﬁcity (43%) due to false positives that are
seen in every subset. This may well be detection of recurrent or
residual disease not seen by our standard methods. Only close
follow-up will determine if these “false positive” patients recur
before the “true negative” patients. This sensitive and quick serum
analysis may prove to be an excellent tool for monitoring MM
patients after treatment.
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AUTOLOGOUS VERSUS ALLOGENEIC STEM CELL TRANSPLANT FOR
MULTIPLE MYELOMA
Arora, M., McGlave, P.B., Burns, L.J., Miller, J.S., Barker, J.N.,
Defor, T.E., Weisdorf, D.J. University of Minnesota, Minneapolis, MN
We report results of a comparative analysis of 87 patients with
multiple myeloma, treated with either autologous PBSCT (n 70)
or allogeneic sibling donor myeloablative transplant (n 17) using
cyclophosphamide and fractionated TBI conditioning. Autologous
transplant recipients were signiﬁcantly older (median age 53 vs. 47
years, p  .01) and had a longer period between diagnosis and
transplant (10.5 vs 7 months, p .03). Autologous transplant led to
lower transplant related mortality (TRM) of 4% (95% CI 0-36%)
vs. 18% (0-9%) in the allogeneic patients at 100 days post trans-
plant (p  .02). More frequent complete responses (CR) were seen
in the allogeneic patients (64% (95%CI 37-91%) vs. 34% (95%CI
23-45%) in the autologous patients, p  .09). In the autologous
patients, overall survival of 86% (95% CI 80-95%) at one year and
50% (95% CI 47-75%) at 4 years was seen vs. 64% (95% CI
40-87%) at one year and at 4 years in the allogeneic patients. In
patients surviving beyond one year, survival was superior in the
allogeneic transplant patients (100% (95% CI 100-100%) versus
58% (95% CI 41-75%) at 4 years, p  .02). The cumulative
incidence of relapse showed a trend towards higher relapse in the
autologous patients (73% (95% CI 55-90%) versus (37% (95% CI
11-63%) in allogeneic patients at 4 years, p  .1). In multiple
regression analysis, attainment of a CR or PR pre transplant (OR
3.4, 95% CI 0.9-12.9, p  .06),  1 year between diagnosis and
transplant (OR 3.8, 95% CI 1.1-13.8, p  .04),  2 regimens of
chemotherapy (OR 8.3, 95% CI 2.2-31.3, p .01) were associated
with good response. Early transplant with 4 chemo cycles (RR of
failure 0.5 (95% CI 0.2-0.9, p  0.04) and attainment of CR or PR
post transplant (RR 0.4 (95% CI 0.2-0.7, p  0.01) was a signiﬁ-
cant predictor of good overall and progression free survival. Older
age at transplant (RR 1.1, 95% CI 0.9-1.3, p  .06), allogeneic
transplant (RR 11.0, 95% CI 2.3-53.7, p  .01), and  4 cycles of
pretransplant chemotherapy (RR 6.3, 95% CI 1.1-35.7, p  .04)
were each signiﬁcant predictors of high TRM. We observed good
clinical tolerance of the myeloablative conditioning regimen fol-
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